摘要
目的:观察孟鲁司特对哮喘患儿血清IL-4、TNF-α和IFN-γ水平的影响,探讨其防治哮喘的机制。方法:选择180例哮喘急性发作期患儿,随机分为治疗组和对照组。正常组为90例同一时期体检儿童。治疗组在对照组常规综合治疗的基础上,加用孟鲁司特5 mg/d,1次/d,睡前口服,连用半年。结果:治疗半年后,治疗组血清IL-4、TNF-α水平较对照组明显下降,而血清IFN-γ水平较对照组明显上升,均有显著差异;并且治疗组与正常组相接近。结论:孟鲁司特能降低哮喘患儿血清IL-4、TNF-α水平,增高血清IFN-γ水平,减轻免疫炎症反应,在哮喘的抗感染治疗中起重要作用。
Objective： To investigate the effect of Montelukast on serum IL-4,TNF-α and IFN-γ in children with asthma,and to discuss the mechanism of preventing and controlling asthma.Methods： 180 children with acute attack asthma were randomly divided into treatment group and control group,90 cases for the same period check-up children served as the normal group.Based on the basic treatment as control group,the treatment group was also given Montelukast 5 mg/d bedtime orally,1 time per day for half a year.Results： The serum IL-4 and TNF-α of treatment group half a year after treatment were significantly decreased compared with those of the control group,the serum IFN-γ was significantly increased compared with that of control group,and the treatment group was similar with the normal group.Conclusion： Montelukast can reduce IL-4 and TNF-α levels,can increase IFN-γ level in children with asthma,and can also decrease inflammatory reaction,Montelukast can be used to treat asthma effectively.
出处
《中国医药导报》
CAS
2011年第4期70-71,共2页
China Medical Herald
